Treprostinil liposomal (Pharmosa BioPharm)

N/A

Report date: 2025/07/01 14:45:56

Base Information

Drug NameTreprostinil liposomal (Pharmosa BioPharm)
Drug Alias Nameliposomal treprostinil (Pharmosa BioPharm)Sustained-Release Inhaled Treprostinil (Pharmosa BioPharm)YutrepiaL-606 (Pharmosa Biopharm)
ClassificationSmall molecules
Mechanisms of ActionProstanoid IP receptor agonists
TargetsProstanoid IP receptor
Therapy Area/IndicationsLung Diseases, InterstitialPulmonary Arterial Hypertension
Global Approved IndicationsLung Diseases, InterstitialPulmonary Arterial Hypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/05/23
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPharmosa Biopharm Inc
China Registration ClassN/A

Develop Information

Active CompaniesLiquidia CorpMenagen Pharmaceutical Industries LLCLiquidia Technologies Inc +[4] 
Inactive CompaniesN/A
Active IndicationsLung Diseases, InterstitialPulmonary Arterial Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A